Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients

ABSTRACT: Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib : an active agent only in non progressive patients. BACKGROUND: Imatinib is a standard treatment for advanced/metastatic GIST and in adjuvant setting. Anaemia is...

Descripción completa

Detalles Bibliográficos
Autores principales: Duffaud, Florence, Even, Caroline, Ray-Coquard, Isabelle, Bompas, Emmanuelle, Khoa-Huynh, Thanh, Salas, Sebastien, Cassier, Philippe, Dufresne, Armelle, Bonvalot, Sylvie, Ducimetiere, Francoise, Le Cesne, Axel, Blay, Jean-Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502564/
https://www.ncbi.nlm.nih.gov/pubmed/22950685
http://dx.doi.org/10.1186/2045-3329-2-11
_version_ 1782250368391970816
author Duffaud, Florence
Even, Caroline
Ray-Coquard, Isabelle
Bompas, Emmanuelle
Khoa-Huynh, Thanh
Salas, Sebastien
Cassier, Philippe
Dufresne, Armelle
Bonvalot, Sylvie
Ducimetiere, Francoise
Le Cesne, Axel
Blay, Jean-Yves
author_facet Duffaud, Florence
Even, Caroline
Ray-Coquard, Isabelle
Bompas, Emmanuelle
Khoa-Huynh, Thanh
Salas, Sebastien
Cassier, Philippe
Dufresne, Armelle
Bonvalot, Sylvie
Ducimetiere, Francoise
Le Cesne, Axel
Blay, Jean-Yves
author_sort Duffaud, Florence
collection PubMed
description ABSTRACT: Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib : an active agent only in non progressive patients. BACKGROUND: Imatinib is a standard treatment for advanced/metastatic GIST and in adjuvant setting. Anaemia is frequently observed in patients with advanced GIST, and is one of the most frequent side effects of imatinib with grade 3–4 anaemia in 10% of patients. Whether EPO treatment is useful in the management of GIST patients receiving imatinib treatment is unknown. METHODS: A retrospective study of EPO treatment in GIST patients receiving imatinib was undertaken in 4 centres. Thirty four patients received EPO treatment among the 319 GIST patients treated with imatinib in clinical trials or with compassionate use between 2001 and 2003. The efficacy of EPO on the anaemia of patients with GIST treated with imatinib was analyzed. RESULTS: There were 18 males and 16 females with a median age of 59 years. Median WHO-PS was 1. Primary tumour sites were mainly gastric (32%) and small bowel (29%). Sites of metastases were mainly liver (82%) and peritoneum (79%). The median delay between the initiation of imatinib treatment and EPO was 58 days (range 0–553). Median haemoglobin (Hb) level prior to EPO was 9 g/dL (range 6,9-11,8) and 11,7 g/dL (range 6,8-14,4) after 2 months. An increase of more than 2 g/dL was observed in 18 (53%) of patients. None of the 7 patients who progressed (PD) under imatinib treatment (400 mg/day) experienced HB response, as compared to 66% (18/27) of the remaining patients (PR + SD) (p = 0,002). Primary tumour site, liver metastases, peritoneal metastases, age, gender did not correlate with HB response to EPO. Response to EPO was observed in 2/11 patients receiving high-dose imatinib (800 mg/day) vs 16/23 of others. Using logistic regression, only PD before EPO treatment was retained as a predictive factor for EPO response. CONCLUSION: EPO enables to increase Hb in most anaemic GIST patients who do not progress under imatinib, but not in patients with progressive disease.
format Online
Article
Text
id pubmed-3502564
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35025642012-11-22 Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients Duffaud, Florence Even, Caroline Ray-Coquard, Isabelle Bompas, Emmanuelle Khoa-Huynh, Thanh Salas, Sebastien Cassier, Philippe Dufresne, Armelle Bonvalot, Sylvie Ducimetiere, Francoise Le Cesne, Axel Blay, Jean-Yves Clin Sarcoma Res Research ABSTRACT: Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib : an active agent only in non progressive patients. BACKGROUND: Imatinib is a standard treatment for advanced/metastatic GIST and in adjuvant setting. Anaemia is frequently observed in patients with advanced GIST, and is one of the most frequent side effects of imatinib with grade 3–4 anaemia in 10% of patients. Whether EPO treatment is useful in the management of GIST patients receiving imatinib treatment is unknown. METHODS: A retrospective study of EPO treatment in GIST patients receiving imatinib was undertaken in 4 centres. Thirty four patients received EPO treatment among the 319 GIST patients treated with imatinib in clinical trials or with compassionate use between 2001 and 2003. The efficacy of EPO on the anaemia of patients with GIST treated with imatinib was analyzed. RESULTS: There were 18 males and 16 females with a median age of 59 years. Median WHO-PS was 1. Primary tumour sites were mainly gastric (32%) and small bowel (29%). Sites of metastases were mainly liver (82%) and peritoneum (79%). The median delay between the initiation of imatinib treatment and EPO was 58 days (range 0–553). Median haemoglobin (Hb) level prior to EPO was 9 g/dL (range 6,9-11,8) and 11,7 g/dL (range 6,8-14,4) after 2 months. An increase of more than 2 g/dL was observed in 18 (53%) of patients. None of the 7 patients who progressed (PD) under imatinib treatment (400 mg/day) experienced HB response, as compared to 66% (18/27) of the remaining patients (PR + SD) (p = 0,002). Primary tumour site, liver metastases, peritoneal metastases, age, gender did not correlate with HB response to EPO. Response to EPO was observed in 2/11 patients receiving high-dose imatinib (800 mg/day) vs 16/23 of others. Using logistic regression, only PD before EPO treatment was retained as a predictive factor for EPO response. CONCLUSION: EPO enables to increase Hb in most anaemic GIST patients who do not progress under imatinib, but not in patients with progressive disease. BioMed Central 2012-09-05 /pmc/articles/PMC3502564/ /pubmed/22950685 http://dx.doi.org/10.1186/2045-3329-2-11 Text en Copyright ©2012 Duffaud et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Duffaud, Florence
Even, Caroline
Ray-Coquard, Isabelle
Bompas, Emmanuelle
Khoa-Huynh, Thanh
Salas, Sebastien
Cassier, Philippe
Dufresne, Armelle
Bonvalot, Sylvie
Ducimetiere, Francoise
Le Cesne, Axel
Blay, Jean-Yves
Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
title Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
title_full Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
title_fullStr Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
title_full_unstemmed Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
title_short Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
title_sort recombinant erythropoietin for the anaemia of patients with advanced gastrointestinal stromal tumours (gist) receiving imatinib: an active agent only in non progressive patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502564/
https://www.ncbi.nlm.nih.gov/pubmed/22950685
http://dx.doi.org/10.1186/2045-3329-2-11
work_keys_str_mv AT duffaudflorence recombinanterythropoietinfortheanaemiaofpatientswithadvancedgastrointestinalstromaltumoursgistreceivingimatinibanactiveagentonlyinnonprogressivepatients
AT evencaroline recombinanterythropoietinfortheanaemiaofpatientswithadvancedgastrointestinalstromaltumoursgistreceivingimatinibanactiveagentonlyinnonprogressivepatients
AT raycoquardisabelle recombinanterythropoietinfortheanaemiaofpatientswithadvancedgastrointestinalstromaltumoursgistreceivingimatinibanactiveagentonlyinnonprogressivepatients
AT bompasemmanuelle recombinanterythropoietinfortheanaemiaofpatientswithadvancedgastrointestinalstromaltumoursgistreceivingimatinibanactiveagentonlyinnonprogressivepatients
AT khoahuynhthanh recombinanterythropoietinfortheanaemiaofpatientswithadvancedgastrointestinalstromaltumoursgistreceivingimatinibanactiveagentonlyinnonprogressivepatients
AT salassebastien recombinanterythropoietinfortheanaemiaofpatientswithadvancedgastrointestinalstromaltumoursgistreceivingimatinibanactiveagentonlyinnonprogressivepatients
AT cassierphilippe recombinanterythropoietinfortheanaemiaofpatientswithadvancedgastrointestinalstromaltumoursgistreceivingimatinibanactiveagentonlyinnonprogressivepatients
AT dufresnearmelle recombinanterythropoietinfortheanaemiaofpatientswithadvancedgastrointestinalstromaltumoursgistreceivingimatinibanactiveagentonlyinnonprogressivepatients
AT bonvalotsylvie recombinanterythropoietinfortheanaemiaofpatientswithadvancedgastrointestinalstromaltumoursgistreceivingimatinibanactiveagentonlyinnonprogressivepatients
AT ducimetierefrancoise recombinanterythropoietinfortheanaemiaofpatientswithadvancedgastrointestinalstromaltumoursgistreceivingimatinibanactiveagentonlyinnonprogressivepatients
AT lecesneaxel recombinanterythropoietinfortheanaemiaofpatientswithadvancedgastrointestinalstromaltumoursgistreceivingimatinibanactiveagentonlyinnonprogressivepatients
AT blayjeanyves recombinanterythropoietinfortheanaemiaofpatientswithadvancedgastrointestinalstromaltumoursgistreceivingimatinibanactiveagentonlyinnonprogressivepatients